Novartis's Tislelizumab Takes First Step On US Approval Path
Aiming To Reach Crowded Checkpoint Inhibitor Market
Novartis has filed the PD-1 inhibitor tislelizumab, licensed from BeiGene, for second-line esophageal cancer with the FDA, the first submission outside China for the closely-watched therapy.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Roche shores up oncology; Janssen’s multiple myeloma strategy; gene therapy safety; a new PD-1 inhibitor moves forward in the US; and herd immunity and COVID.
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker